Stocksigma LogoStocksigma Logo

Beta Drugs Q2 FY27 Monitoring Agency Report Shows Zero Deviations in Preferential Issue Utilization

Brickwork Ratings released the Sixth Monitoring Agency Report for Beta Drugs Ltd. for the quarter ended 30th Sep'26, tracking funds raised via a ₹117.02

Beta Drugs Q2 FY27 Monitoring Agency Report Shows Zero Deviations in Preferential Issue Utilization

Beta Drugs Ltd · Others (Uncategorized) · 12 Nov 2026, 5:06 pm

Beta Drugs Q2 FY27 Monitoring Agency Report Shows Zero Deviations in Preferential Issue Utilization Brickwork Ratings released the Sixth Monitoring Agency Report for Beta Drugs Ltd. for the quarter ended 30th Sep'26, tracking funds raised via a ₹117.02 crore preferential issue of Equity Shares and CCDs (net ₹117.01 crore received). Cumulative utilization stood at ₹47.37 crore with ₹0.00 crore deployed during the quarter, leaving ₹69.64 crore unutilized. The unutilized balance is parked across fixed deposits in HDFC Bank and ICICI Bank yielding 5.50%–6.60%, alongside ₹0.06 crore in the share capital account. No deviations or project implementation delays were reported.

Original exchange filing (PDF)

More announcements from Beta Drugs Ltd

All Beta Drugs Ltd announcements